Perception and Attitudes toward COVID- 19 Vaccines in Jordan: Lessons for future Pandemics

Main Article Content

Dalal Alnatour
Razan I. Nassar
Yara Salhi
Samar Thiab
Ahmad R Alsayed


COVID-19, Jordan, Vaccine, Attitude, Perception


Objective: This study aimed to assess Jordanians’ perception and attitudes toward COVID-19 vaccines authorized for use in Jordan. Another objective was to evaluate the population’s confidence in vaccine efficacy, their fears of the vaccines, and their perceptions and attitudes after vaccination. Methods: This cross-sectional study was conducted over four months (August 2021- December 2021) and included the general Jordanian population above 18 years old. Results: A total of 398 participants were included in the study, with the majority (around 81.0%) received at least one dose of any of COVID-19 vaccines approved for use in Jordan. Most non-vaccinated participants (67.4%) were either unwilling to receive the COVID-19 vaccine or unsure. The main reasons for receiving the vaccine were: family protection, self-protection, global efforts to fight the virus and local restrictions, with some variability between vaccinated and non-vaccinated. The major reasons for fear of COVID-19 vaccines were limited research, vaccine effectiveness, and vaccine side effects. Pfizer-BioNTech vaccine was the most trusted vaccine by vaccinated and non-vaccinated participants (47.8% and 57.9%, respectively), and Oxford- AstraZeneca was the most feared by them (42.2% and 57.9%, respectively). Internet websites (>85.0%), social media platforms (>70.0%), relatives and friends (>69.0%), and news applications (>60.0%) were the major sources of information about the COVID-19 vaccines among participants. Conclusion: Our results revealed that hesitation in receiving the vaccine remains a challenge in Jordan, as in other countries. The findings also show that participants, regardless of their vaccination status, had many concerns about the four types of vaccines approved for use in Jordan during the study conduction period. Moreover, the participants’ perceptions and attitudes towards the vaccines were variable between vaccinated and non-vaccinated participants and were variable for the four types of vaccines.

Abstract 466 | PDF Downloads 484


1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard: World Health Organization; 2020.
2. Lenzen M, Li M, Malik A, et al. Global socio-economic losses and environmental gains from the Coronavirus pandemic. PLoS One. 2020;15(7):e0235654.
3. Betancourt JA, Rosenberg MA, Zevallos A, et al. The Impact of COVID-19 on Telemedicine Utilization Across Multiple Service Lines in the United States. Healthcare (Basel). 2020;8(4):380.
4. Rapanta C, Botturi L, Goodyear P, et al. Online University Teaching During and After the Covid-19 Crisis: Refocusing Teacher Presence and Learning Activity. Postdigital Science and Education. 2020;2(3):923-945.
5. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. Journal of Medical Virology. 2020;92(9):726-730.
6. Jensehaugen J. Jordan and COVID-19: Effective Response at a High Cost. PRIO Middle East Center Mideast Policy Brief No. 03- 2020. 2020.
7. Ministry of Health. COVID-19 Updates in Jordan. Ministry of Health: Ministry of Health; 2020.
8. Nowakowska J, Sobocińska J, Lewicki M, et al. When science goes viral: The research response during three months of the COVID-19 outbreak. Biomed Pharmacother. 2020;129:110451.
9. Rzymski P, Nowicki M, Mullin GE, et al. Quantity does not equal quality: Scientific principles cannot be sacrificed. Int Immunopharmacol. 2020;86(1):106711.
10. Gianola S, Jesus TS, Bargeri S, et al. Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic. PLoS One. 2020;15(10):e0240123.
11. Krause PA-O, Gruber MF. Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations. 2020;383(19):e197.
12. Livingston EH, Malani PN, Creech CBJJ. The Johnson & Johnson Vaccine for COVID-19. 2021;325:1575. w1nnlf
13. Phadke VK, Bednarczyk RA, Salmon DA, et al. Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. JAMA. 2016;315(11):1149.
14. Dubé E, Laberge C, Guay M, et al. Vaccine hesitancy: an overview. Hum Vaccin Immunother. 2013;9:1763-1773.
15. Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35:775-779.
16. Callaghan T, Moghtaderi A, Lueck JA, et al. Correlates and disparities of COVID-19 vaccine hesitancy. 2020. https://doi. org/10.2139/ssrn.3667971
17. Al-Qerem W, Jarab AS, Qarqaz R, et al. Attitudes of a sample of Jordanian young adults toward different available COVID-19 vaccines. Vacunas. 2022;23:S56-s63.
18. Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Ann Intern Med. 2020;173(12):964-973.
19. Suvvari TK, Kutikuppala LVS, Tsagkaris C, et al. Post-COVID-19 complications: Multisystemic approach. J Med Virol. 2021;93(12):6451-6455.
20. Štěpánek L, Janošíková M, Nakládalová M, et al. Motivation to COVID-19 Vaccination and Reasons for Hesitancy in Employees of a Czech Tertiary Care Hospital: A Cross-Sectional Survey. Vaccines (Basel). 2021;9(8):863.
21. Persad G, Peek ME, Emanuel EJ. Fairly Prioritising Groups for Access to COVID-19 Vaccines. JAMA. 2020;324(16):1601-1602.
22. Cordero DA. Rebuilding public trust: a clarified response to COVID-19 vaccine hesitancy predicament. J Public Health (Oxf). 2021;43(2):e303-e304.
23. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. The European Journal of Health Economics. 2020;21(7):977-982.
24. Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel). 2020;8(1):278-284.
25. Yorita KL, Holman RC, Sejvar JJ, et al. Infectious disease hospitalisations among infants in the United States. Pediatrics. 2008;121(2):244-252.
26. Brownlie J, Howson A. ‘Between the demands of truth and government’: health practitioners, trust and immunisation work. Soc Sci Med. 2006;62:433-443.
27. Larson HJ, Cooper LZ, Eskola J, et al. Addressing the vaccine confidence gap. Lancet. 2011;378(9790):526-535. https://doi. org/10.1016/s0140-6736(11)60678-8
28. Piltch-Loeb R, Savoia E, Goldberg B, et al. Examining the effect of information channel on COVID-19 vaccine acceptance. PLoS One. 2021;16(5):e0251095.

Most read articles by the same author(s)